Vir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity. Vir CEO Marianne De Backer discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily. (Source: Bloomberg)